An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours (clinicaltrials.gov) - Oct 6, 2026 - P2 | N=66 | Active, not recruiting | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027
Trial completion date • Trial primary completion date • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor • SSTR
|